Prostate Clinical Trials in Boston, Massachusetts
79 recruitingBoston, Massachusetts
Showing 1–20 of 79 trials
Recruiting
Phase 1
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Metastatic Castration-resistant Prostate Cancer (mCRPC)Small Cell Lung Cancer ( SCLC )Follicular Lymphoma ( FL)
Pfizer453 enrolled83 locationsNCT03460977
Recruiting
Phase 3
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Oligometastatic Prostate Cancer (OMPC)
Novartis Pharmaceuticals450 enrolled147 locationsNCT05939414
Recruiting
Phase 1
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Breast NeoplasmsStomach NeoplasmsColorectal Neoplasms+4 more
Eli Lilly and Company421 enrolled30 locationsNCT07114601
Recruiting
Not Applicable
Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer
Prostate Cancer
Varian, a Siemens Healthineers Company132 enrolled8 locationsNCT05804318
Recruiting
Phase 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Solid Tumor+7 more
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Not Applicable
Video Education With Result Dependent dIsclosure
Breast CancerColorectal, CancerPancreatic Cancer+6 more
Dana-Farber Cancer Institute1,020 enrolled1 locationNCT05225428
Recruiting
Phase 1
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Triple-Negative Breast CancerEsophageal CancerPancreatic Cancer+11 more
Eli Lilly and Company420 enrolled33 locationsNCT06465069
Recruiting
Phase 1
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Large Cell Neuroendocrine Carcinoma of the LungSmall Cell Lung CarcinomaNeuroendocrine Prostate Cancer+1 more
Novartis Pharmaceuticals116 enrolled6 locationsNCT07006727
Recruiting
Phase 1Phase 2
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Breast CancerEsophageal CancerPancreatic Cancer+13 more
ModeX Therapeutics, An OPKO Health Company285 enrolled6 locationsNCT06239194
Recruiting
Phase 1
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Triple-Negative Breast CancerColorectal, CancerBiliary Tract Cancer+8 more
Zumutor Biologics Inc.100 enrolled3 locationsNCT06451497
Recruiting
Phase 1Phase 2
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Breast CancerColorectal, CancerGastric Cancer+10 more
858 Therapeutics, Inc.120 enrolled14 locationsNCT06395519
Recruiting
Phase 1Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Breast CancerTriple-Negative Breast CancerColorectal, Cancer+26 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Phase 1
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Breast CancerColorectal, CancerOvarian Cancer+6 more
IDEAYA Biosciences216 enrolled27 locationsNCT05787587
Recruiting
Phase 1
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Breast CancerTriple-Negative Breast CancerEsophageal Cancer+9 more
SystImmune Inc.470 enrolled39 locationsNCT05983432
Recruiting
Phase 1
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Prostate CancerMetastatic Castration-resistant Prostate CancerCastration-Resistant Prostatic Cancer
Janux Therapeutics272 enrolled35 locationsNCT05519449
Recruiting
Not Applicable
Stereotactic Magnetic Resonance Guided Radiation Therapy
Prostate CancerLung CancerSpine Metastases+10 more
Dana-Farber Cancer Institute397 enrolled2 locationsNCT04115254
Recruiting
Phase 1
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Metastatic Breast CancerAdvanced or Metastatic ER+ HER2- Breast Cancer (mBC)Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)+3 more
Olema Pharmaceuticals, Inc.180 enrolled8 locationsNCT06784193
Recruiting
Phase 1Phase 2
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Small Cell Lung Cancer ( SCLC )Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)Neuroendocrine Carcinomas (NEC)+3 more
Phanes Therapeutics203 enrolled12 locationsNCT05652686
Recruiting
Phase 1Phase 2
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Endometrial CancerAdvanced Solid TumorDiffuse Large B Cell Lymphoma+5 more
Novartis Pharmaceuticals275 enrolled60 locationsNCT04104776
Recruiting
Not Applicable
Comprehensive Outcomes for After Cancer Health
Breast CancerMetastatic Breast CancerGastric Cancer+8 more
Pack Health625 enrolled7 locationsNCT05349227